-
1042714-25MGThis product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the
-
A-119-1MLA Certified Solution Standard for use in LC or GC applications including forensic drug analysis or calibrator preparation. Aripiprazole is marketed as the atypical antipsychotic Abilify ® for the treatment of schizophrenia, bipolar disorder
-
A-081-1MLAripiprazole, marketed as Abilify ® , is an atypical antipsychotic and antidepressant drug used to treat schizophrenia, bipolar disorder, and clinical depression. This new internal standard is suitable for the quantitation of aripiprazole in
-
D330770-10mgDehydro Aripiprazole Hydrochloride is a metabolite of Aripiprazole which is a selective dopamine D2-receptor antagonist with dopamine autoreceptor agonist activity.
-
D330770-5mgDehydro Aripiprazole Hydrochloride is a metabolite of Aripiprazole which is a selective dopamine D2-receptor antagonist with dopamine autoreceptor agonist activity.
-
D-053-1MLDehydro Aripiprazole is the primary, active metabolite of aripiprazole, marketed as the atypical antipsychotic Abilify ® for the treatment of schizophrenia, bipolar disorder, and clinical depression. This new certified solution standard is
-
D-178-1MLThis stable-labeled internal standard is suitable for use in LC/MS or GC/MS applications including forensic or clinical toxicology analysis and urine drug testing. Dehydro Aripiprazole is the primary, active metabolite of aripiprazole, marketed as
-